ZNF213抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P09229(ZNF213 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P09229(ZNF213 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The zinc finger protein 213 (ZNF213), also known as ANKR1 or MGC21881. is a member of the Krüppel-associated box (KRAB)-containing zinc finger protein family. These proteins are characterized by tandem C2H2-type zinc finger domains, which facilitate DNA or RNA binding, and a KRAB domain involved in transcriptional repression. ZNF213 is evolutionarily conserved and ubiquitously expressed in human tissues, with roles in regulating gene expression, cell proliferation, and differentiation.

Recent studies have linked ZNF213 to human diseases. Notably, a 2017 study in *Nature Genetics* identified ZNF213 as a susceptibility gene for moyamoya disease, a rare cerebrovascular disorder, with the p.R4810K variant showing strong association in East Asian populations. Additionally, ZNF213 has been implicated in cancer biology, acting as a potential tumor suppressor in hepatocellular carcinoma by modulating Wnt/β-catenin signaling.

ZNF213 antibodies are critical tools for investigating these mechanisms. They enable the detection and localization of ZNF213 in tissues or cells via techniques like Western blotting (WB), immunohistochemistry (IHC), and immunofluorescence (IF). Specific antibodies also facilitate chromatin immunoprecipitation (ChIP) to identify DNA regions bound by ZNF213. aiding in mapping its regulatory targets. Commercial antibodies are typically validated for specificity using knockout cell lines or siRNA knockdown. Researchers utilize these reagents to explore ZNF213's roles in vascular development, tumor suppression, and epigenetic regulation, with therapeutic implications for moyamoya disease and cancers.